Tower Research Capital LLC TRC increased its position in shares of Dr.Reddy’s Laboratories Ltd (NYSE:RDY) by 15,124.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,771 shares of the company’s stock after purchasing an additional 21,628 shares during the period. Tower Research Capital LLC TRC’s holdings in Dr.Reddy’s Laboratories were worth $701,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in RDY. Wells Fargo & Company MN increased its position in Dr.Reddy’s Laboratories by 27.2% during the first quarter. Wells Fargo & Company MN now owns 32,212 shares of the company’s stock worth $1,053,000 after purchasing an additional 6,896 shares during the last quarter. Northern Trust Corp increased its position in shares of Dr.Reddy’s Laboratories by 48.3% during the first quarter. Northern Trust Corp now owns 362,685 shares of the company’s stock valued at $11,856,000 after acquiring an additional 118,157 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Dr.Reddy’s Laboratories during the first quarter valued at about $5,893,000. Mondrian Investment Partners LTD increased its position in shares of Dr.Reddy’s Laboratories by 112.7% during the first quarter. Mondrian Investment Partners LTD now owns 758,866 shares of the company’s stock valued at $24,519,000 after acquiring an additional 402,080 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Dr.Reddy’s Laboratories by 18.9% during the first quarter. Dimensional Fund Advisors LP now owns 693,335 shares of the company’s stock valued at $22,669,000 after acquiring an additional 110,431 shares during the last quarter. Hedge funds and other institutional investors own 12.27% of the company’s stock.

Shares of NYSE RDY traded up $0.58 during midday trading on Friday, hitting $33.17. The company’s stock had a trading volume of 363,125 shares, compared to its average volume of 369,583. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.19 and a current ratio of 1.64. Dr.Reddy’s Laboratories Ltd has a 1 year low of $28.13 and a 1 year high of $39.96. The firm has a market cap of $5.74 billion, a price-to-earnings ratio of 32.84 and a beta of 0.13.

Dr.Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, July 26th. The company reported $0.40 EPS for the quarter. Dr.Reddy’s Laboratories had a net margin of 9.41% and a return on equity of 11.74%. The business had revenue of $543.00 million during the quarter, compared to analyst estimates of $542.20 million. Equities analysts predict that Dr.Reddy’s Laboratories Ltd will post 1.33 EPS for the current fiscal year.

A number of equities research analysts have weighed in on RDY shares. ValuEngine cut shares of Dr.Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th. Zacks Investment Research cut shares of Dr.Reddy’s Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th.

Dr.Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Read More: What are the Benefits of Index Funds?

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.